News
Starting on a weight loss medication has helped Joie Armstrong prioritize caring for herself, including finding more ...
Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.
Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...
Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...
Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...
A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study ...
Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...
Body image is part physical and part mental. If weight loss alone isn't helping, strategies from body image psychology can ...
Fifteen Connecticut companies made the 2025 Fortune 500 list of the largest U.S. corporations, which was announced Monday-- a sign of stability in the state's corporate sector. Bloomfield- ...
Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic ...
A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...
Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results